Two Sigma Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-47,800
| Closed | -$88.4K | – | 2770 |
|
|
2023
Q1 | $88.4K | Sell |
47,800
-332,700
| -87% | -$412K | ﹤0.01% | 2399 |
|
|
2022
Q4 | $422K | Buy |
380,500
+96,700
| +34% | +$138K | ﹤0.01% | 1947 |
|
|
2022
Q3 | $664K | Sell |
283,800
-36,700
| -11% | -$130K | ﹤0.01% | 1723 |
|
|
2022
Q2 | $971K | Sell |
320,500
-6,000
| -2% | -$29.2K | ﹤0.01% | 1610 |
|
|
2022
Q1 | $2.22M | Sell |
326,500
-199,000
| -38% | -$1.42M | 0.01% | 1194 |
|
|
2021
Q4 | $4.39M | Buy |
525,500
+149,000
| +40% | +$1.23M | 0.01% | 823 |
|
|
2021
Q3 | $2.8M | Buy |
376,500
+158,900
| +73% | +$984K | 0.01% | 1070 |
|
|
2021
Q2 | $1.48M | Buy |
217,600
+134,800
| +163% | +$1.12M | ﹤0.01% | 1447 |
|
|
2021
Q1 | $850K | Buy |
+82,800
| New | +$907K | ﹤0.01% | 1739 |
|
|
2020
Q3 | – | Sell |
-25,300
| Closed | -$175K | – | 2697 |
|
|
2020
Q2 | $175K | Sell |
25,300
-24,100
| -49% | -$130K | ﹤0.01% | 2279 |
|
|
2020
Q1 | $235K | Sell |
49,400
-68,700
| -58% | -$395K | ﹤0.01% | 2113 |
|
|
2019
Q4 | $1.03M | Sell |
118,100
-22,800
| -16% | -$123K | ﹤0.01% | 1564 |
|
|
2019
Q3 | $469K | Sell |
140,900
-11,000
| -7% | -$44K | ﹤0.01% | 1737 |
|
|
2019
Q2 | $752K | Sell |
151,900
-41,900
| -22% | -$222K | ﹤0.01% | 1648 |
|
|
2019
Q1 | $1.2M | Sell |
193,800
-73,600
| -28% | -$356K | ﹤0.01% | 1435 |
|
|
2018
Q4 | $901K | Buy |
267,400
+59,700
| +29% | +$279K | ﹤0.01% | 1528 |
|
|
2018
Q3 | $1.35M | Buy |
207,700
+129,200
| +165% | +$961K | ﹤0.01% | 1390 |
|
|
2018
Q2 | $601K | Buy |
+78,500
| New | +$1.13M | ﹤0.01% | 1845 |
|
Other funds holding JNCE
Two Sigma Advisers's JNCE Position: Q2 2023 in Review
Two Sigma Advisers sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 47,800 shares — an estimated $88.4K sold.
Two Sigma Advisers first reported a position in JNCE in Q2 2018 and held it in 18 quarters. The position peaked at $4.39M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Two Sigma Advisers reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Two Sigma Advisers sold 47,800 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $88.4K.
- Two Sigma Advisers first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
- Two Sigma Advisers's Jounce Therapeutics, Inc. Common Stock position peaked at $4.39M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.